Vecchioli Scaldazza Carlo, Morosetti Carolina
Operating Unit of Urogynecology, ASUR, Jesi, Italy.
Urol Int. 2016;97(3):325-329. doi: 10.1159/000445808. Epub 2016 Apr 20.
We assessed clinical and urodynamic effects of solifenacin versus mirabegron in women with overactive bladder (OAB) syndrome.
Eighty women with OAB were randomized into 2 groups. In group A, the patients received solifenacin 5 mg once a day for 12 weeks; in group B, the patients received mirabegron 50 mg once a day for 12 weeks. Symptoms were assessed with OAB Symptom Score (OABSS). Patients underwent urodynamic investigation with pressure flow study. OABSS and urodynamic study were performed before and after treatment.
Both solifenacin and mirabegron were effective in improving OAB symptoms. Mirabegron showed greater tolerability with fewer patients discontinuing therapy because of side effects. Both solifenacin and mirabegron were effective in improving the storage function in the pressure flow study, but solifenacin showed a significant reduction of the detrusor pressure in the voiding phase with an increase in the postvoid residual urine volume.
Mirabegron has shown to be a drug with the better balance between efficacy and tolerability in women with OAB.
我们评估了索利那新与米拉贝隆对膀胱过度活动症（OAB）综合征女性患者的临床及尿动力学影响。
80名OAB女性患者被随机分为两组。A组患者接受索利那新5毫克每日一次，共12周；B组患者接受米拉贝隆50毫克每日一次，共12周。采用OAB症状评分（OABSS）评估症状。患者接受压力流研究进行尿动力学检查。治疗前后均进行OABSS和尿动力学研究。
索利那新和米拉贝隆均能有效改善OAB症状。米拉贝隆耐受性更佳，因副作用而停药的患者较少。在压力流研究中，索利那新和米拉贝隆均能有效改善储尿功能，但索利那新在排尿期逼尿肌压力显著降低，且残余尿量增加。
对于患有OAB的女性，米拉贝隆已被证明是一种在疗效和耐受性之间具有更好平衡的药物。
